GlassScriptPhysician profile
Genevieve K Lynch
NPI 1821654260
$1,480.67
in general payments reported to CMS, 2019-2025
17 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $404 · 2022: $228 · 2023: $248 · 2024: $411 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $781.06 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $117.31 | 2024 | Airsupra |
| Pfizer INC. | $108.06 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.02 | 2024-2025 | Trintellix |
| Novo Nordisk INC | $78.25 | 2022-2025 | Wegovy |
| Lilly USA, LLC | $56.34 | 2021-2024 | Mounjaro |
| Astellas Pharma US INC | $31.56 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $30.07 | 2022-2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Aimmune Therapeutics, INC. | $28.36 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.58 | 2024 | Jardiance |
| Corcept Therapeutics | $21.92 | 2024 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $20.21 | 2022 | |
| Genentech USA, INC. | $17.67 | 2021 | |
| Glaxosmithkline, LLC. | $16.92 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.50 | 2025 | Xifaxan |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.63 | 2022 | |
| Organon LLC | $9.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Genevieve Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.